Tag: molecular diagnostics

This 2018 review underscores the critical role of molecular testing for BRAF mutations, particularly the V600E variant, in guiding treatment strategies for advanced melanoma. Approximately 50% of advanced melanomas harbor BRAF mutations, making them amenable to targeted therapies with BRAF and MEK inhibitors, which have demonstrated significant long-term benefits. The